These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Usefulness of CHA2DS2-VASc Score to predict clinical outcomes of patients undergoing carotid artery stenting.
    Author: Cerşit S, Öcal L, Keskin M, Gürsoy MO, Küp A, Çelik M, Eren H, Akyol S, Dereli S, Türkmen MM.
    Journal: Int J Cardiovasc Imaging; 2021 Mar; 37(3):783-789. PubMed ID: 33103225.
    Abstract:
    The CHA2DS2-VASc score predicts stroke and mortality risk in several cardiovascular diseases regardless of atrial fibrillation. In this study, we aimed to investigate the ability of CHA2DS2-VASc score to predict in-hospital and long-term outcomes in patients undergoing carotid artery stenting (CAS). The study population included 558 patients undergoing CAS. The patients were stratified into three groups based on their CHA2DS2-VASc scores [low (≤ 2, n = 123), moderate (3-5, n = 355) and high (6-8, n = 80)]. In-hospital and 3-year outcomes were compared between the groups. In-hospital rates of ipsilateral and major strokes and death were significantly different between the groups (1.6% vs. 3.9% vs. 16.2%; 1.6% vs. 4.5% vs. 16.2%; 0.8% vs. 3.1% vs. 13.8%, p < 0.001 for all, respectively). At 3 years of follow-up, rates of ipsilateral and major strokes and death were significantly increased in patients with highscore compared to those with moderate and low scores (1.6% vs. 5.8% vs. 13%, p = 0.005; 0.8% vs. 5.2% vs. 13%, p = 0.001; 1.6% vs. 8.4% vs. 15.9%; p = 0.002, respectively). After adjusting for multi-model Cox regression analysis, CHA2DS2-VASc score persisted as an independent prognostic factor for mortality and major stroke in patients undergoing CAS. Higher CHA2DS2-VASc score predicted increased risk of in-hospital and 3- year stroke and mortality in patients undergoing CAS.
    [Abstract] [Full Text] [Related] [New Search]